338840 — Y Biologics Income Statement
0.000.00%
Last trade - 00:00- KR₩365bn
- KR₩342bn
- KR₩6bn
Annual income statement for Y Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
| Standards: | — | — | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 4,847 | 4,151 | 3,479 | 5,763 |
| Cost of Revenue | ||||
| Gross Profit | 2,388 | 1,336 | 2,389 | 4,373 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 22,212 | 22,899 | 24,858 | 12,878 |
| Operating Profit | -17,365 | -18,748 | -21,379 | -7,115 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -17,071 | -18,804 | -20,871 | -6,442 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -17,071 | -18,804 | -20,871 | -6,442 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -17,071 | -18,804 | -20,871 | -6,442 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -17,071 | -18,804 | -20,871 | -6,442 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1,232 | -1,350 | -796 | -526 |
| Dividends per Share |